Suppression of RAGE has been associated with a reversal of drug resistance in experimental models (139), suggesting that RAGE, beyond its involvement in tumor initiation and growth, contributes to developing resistance mechanisms that often limit the effectiveness of therapeutic interventions in pancreatic cancer. The gene discussed is AGER; the disease is pancreatic neoplasm.